FDA Approves Eylea (aflibercept) Injection for Diabetic Retinopathy

Article Link: FDA Approves Eylea (aflibercept) Injection for Diabetic Retinopathy

TARRYTOWN, N.Y., May 13, 2019 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept) Injection to treat all stages of diabetic retinopathy (DR), and thereby…

Source: FDA New Drug Approvals